NCT07436078 Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors
| NCT ID | NCT07436078 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Barbara Ann Karmanos Cancer Institute |
| Condition | Female Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 85 participants |
| Start Date | 2026-04-18 |
| Primary Completion | 2029-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 85 participants in total. It began in 2026-04-18 with a primary completion date of 2029-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to culturally adapt an educational genetic counseling intervention to increase the uptake in genetic counseling and testing among African Americans at risk for heredity cancers. With the help of community stakeholders and clinical genetic professionals the investigators will: * adapt and refine a culturally relevant online educational genetic counseling program for at-risk African Americans * Test the effects of the educational program * collaborate with community leaders and clinical genetic professionals to translate study findings, develop a road map for dissemination to the community, and identify barriers to prepare for future trials. Participants from Detroit Research on Cancer Survivor group will be offered enrollment. Once consent is obtained, questionnaires will be completed before an online genetic counselling intervention immediately after, and at 3 months
Eligibility Criteria
Inclusion Criteria: * Participants enrolled in Detroit Research on Cancer Survivors (Detroit ROCS) * Diagnosis of Primary Breast, prostate, or colorectal cancer on or after 1/1/2013 * have received or currently receiving care at Karmanos Cancer Institute * meet one or more of the National Comprehensive Cancer Network (NCCN) guidelines for cancer genetic testing as described below Female breast 1. personal diagnosis at age ≤50 2. personal history of the triple-negative subtype 3. at least 1 close (first- or second-degree) relative diagnosed with breast cancer at age \<50 4. at least 1 close relative diagnosed with ovarian cancer 5. 2+ close relatives diagnosed with breast or prostate cancer 6. age \<50 AND another primary breast cancer at any age 7. 2+ primary breast cancers at any age OR Prostate 1. personal history of high-risk or very high-risk prostate cancer 2. personal history of regional or metastatic prostate cancer 3. personal history of less than high-risk prostate cancer with a suggestive family history (i.e., father or brother or multiple relatives with prostate cancer diagnosed at age \<60; at least 1 relative with breast, ovarian, or pancreatic cancer; or at least 1 relative with colorectal, ovarian, pancreatic, or kidney cancer) OR Colorectal 1. personal diagnosis at age ≤50 2. at least 1 close relative diagnosed with HNPCC at age \<50 3. at least 2 close relatives diagnosed with an HNPCC cancer at any age 4. colorectal and \>=1 primary endometrial, ovarian, gastric, pancreatic, or prostate Exclusion Criteria: * Previous genetic counseling and/or testing
Contact & Investigator
Felicity WK Harper, Ph.D
PRINCIPAL INVESTIGATOR
Barbara Ann Karmanos Cancer Institute
Frequently Asked Questions
Who can join the NCT07436078 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 79 Years, studying Female Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07436078 currently recruiting?
Yes, NCT07436078 is actively recruiting participants. Contact the research team at phalorej@karmanos.org for enrollment information.
Where is the NCT07436078 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT07436078 clinical trial?
NCT07436078 is sponsored by Barbara Ann Karmanos Cancer Institute. The principal investigator is Felicity WK Harper, Ph.D at Barbara Ann Karmanos Cancer Institute. The trial plans to enroll 85 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.